Biotech SF
San Francisco Bay Area biotech stories.
Tuesday, August 23, 2011
Vivus to raise $45M in stock sale
Drug developer Vivus made a deal with institutional investors, who agreed to buy 6.889 million shares at $6.65 per share. The company will net a little more than $45 million after expenses of about $562,000.
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment